ChemoMetec AS (OCSE:CHEMM) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)

What is ChemoMetec AS LT-Debt-to-Total-Asset?

ChemoMetec AS OCSE:CHEMM +0.15% 99 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates OCSE:CHEMM with a GF Score™ of 99/100 and a GF Value™ of kr549.65 (Modestly Undervalued). The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ChemoMetec AS's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

ChemoMetec AS's long-term debt to total assets ratio declined from Dec. 2024 (0.01) to Dec. 2025 (0.00). It may suggest that ChemoMetec AS is progressively becoming less dependent on debt to grow their business.

ChemoMetec AS (OCSE:CHEMM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ChemoMetec AS LT-Debt-to-Total-Asset Related Terms

ChemoMetec AS LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for ChemoMetec AS's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChemoMetec AS LT-Debt-to-Total-Asset Chart

ChemoMetec AS Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.01

0.00

ChemoMetec AS Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.00	0.01	0.00	0.00

99GF Score

ChemoMetec AS OCSE:CHEMM

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

ChemoMetec AS LT-Debt-to-Total-Asset Calculation

ChemoMetec AS's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )	/	Total Assets (A: Jun. 2025 )
	=	3.015	/	828.046
	=	0.00

ChemoMetec AS's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	2.856	/	783.37
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

ChemoMetec AS (OCSE:CHEMM) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on ChemoMetec AS and its competitors.

Is ChemoMetec AS's LT-Debt-to-Total-Asset too high?

ChemoMetec AS's current LT-Debt-to-Total-Asset is 0.00. Overall, ChemoMetec AS has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does ChemoMetec AS's LT-Debt-to-Total-Asset compare to ABT and SYK?

ChemoMetec AS's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on ChemoMetec AS and its competitors. ChemoMetec AS's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ChemoMetec AS stock overvalued right now?

Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr549.65, compared to a current price of kr407.40 — trading 25.9% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. ChemoMetec AS's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?

Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued. The current stock price of kr407.40 is trading 25.9% below its estimated GF Value™ of kr549.65. GuruFocus considers ChemoMetec AS to be Modestly Undervalued.

Key valuation signals for OCSE:CHEMM:

LT-Debt-to-Total-Asset: 0.00
GF Value™: kr549.65 vs. price of kr407.40 (25.9% below fair value)
GF Score™: 99/100 with 2 warning signs

No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ChemoMetec AS Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies OCSE:EMBLA OCSE:GN OCSE:VIRO OCSE:SMSMED OCSE:AMBU B ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760 STE ZBH XSWX:SOON LSE:SN.PEN

Other Exchanges CHEMMc:UK 0DZ0:UK CHY:Germany

Address Gydevang 43, Allerod, DNK, 3450

Website https://www.chemometec.com

ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.

99GF Score

Get the complete analysis for OCSE:CHEMM

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr407.40

Price

kr549.65

GF Value

View OCSE:CHEMM Analysis

See LT-Debt-to-Total-Asset data for all stocks →